Gerresheimer Extends Lifeline as Audit Chaos and Impairments Test Creditor Patience

Gerresheimer stock jumps 28% in a month but faces accounting probe, factory closure, and Centor sale. Shares remain 53% down YoY, with BaFin investigation and Schuldschein extension to September 2026.

Gerresheimer shares have clawed back more than a quarter of their value over the past month, but the glare of an accounting probe, a factory closure, and an ongoing sale process keeps the company under intense scrutiny. The stock surged nearly 6 percent on a recent Thursday to hit €27.12, bucking a weaker DAX that slipped 0.53 percent on geopolitical jitters and rising bond yields. Since then the equity has edged higher, most recently changing hands at €27.82 — a 28 percent advance over 30 days. Yet on a twelve-month view the shares remain roughly 53 percent in the red, with a 52-week high of €64.40 still out of reach.

The rally comes despite a deepening credibility crisis. Gerresheimer is wrestling with systematic accounting irregularities tied to so-called bill-and-hold transactions, where customers were invoiced before goods were shipped — a violation of IFRS. An independent law firm confirmed the violations, which have so far weighed on €35 million in revenue and €24 million in adjusted EBITDA. Grant Thornton is conducting a separate audit of the 2024 and 2025 books, while Germany's financial regulator BaFin launched an investigation in March 2026 and subsequently widened its probe. The audit oversight body APAS is also examining the case, with a particular focus on KPMG, which had issued an unqualified audit opinion for 2024 despite the disputed transactions.

The delayed annual report for 2025 will not be released until June 2026, and no date has yet been set for first-quarter results. On the operational front, Gerresheimer is shuttering its Chicago Heights plant in the US, a move that will eliminate 172 jobs by the end of September 2026. Production is shifting to existing facilities in Italy and India. The company will book non-cash impairments of between €220 million and €240 million for 2025, linked to the US plant and its Sensile Medical AG subsidiary.

Alongside the restructuring, Gerresheimer is pursuing the sale of its US subsidiary Centor, which makes packaging for prescription drugs, with Morgan Stanley managing the process. A double-digit number of interested parties has already emerged; Centor was carried on the books at €292 million at the end of 2024. A sale would ease balance sheet pressure but also dent profitability, since Centor generates above-average margins — a tension that is not lost on analysts.

A critical lifeline came from creditors. Holders of Schuldschein loans totaling €870 million approved a maturity extension with 96 percent support, giving Gerresheimer until September 30, 2026 to deliver audited financials. Key leverage covenants have been suspended in the meantime, and the company’s banking partners have also backed the extension. Should the deadline pass without a clean audit, financing pressure would mount sharply — a scenario management is desperate to avoid.

On the trading floor, chart technicians note that the stock has nearly reached its 200-day moving average of around €27 — a zone that could either serve as a launchpad or a ceiling. The broader pharmaceutical supply chain is drawing buyers again, as rival Sartorius also jumped more than 4 percent on the same day. Yet short sellers remain cautious: roughly 11 percent of reportable shares are out on loan. Arrowstreet Capital trimmed its short position to 1.99 percent, but that hardly signals a full retreat.

Adding to the legal overhang, the German shareholder protection association DSW is examining potential damages claims against Gerresheimer’s former CEO, former CFO, and the supervisory board. For 2026, the company reaffirmed its operating guidance: revenue between €2.3 billion and €2.4 billion, an adjusted EBITDA margin of 18 to 19 percent, and moderately positive free cash flow. The testated annual report due in June will provide the first hard data in months. The half-year report is scheduled for July 14, 2026, followed by the third-quarter release on October 15.